Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05202379




Registration number
NCT05202379
Ethics application status
Date submitted
10/01/2022
Date registered
21/01/2022
Date last updated
1/06/2023

Titles & IDs
Public title
CC-42344 Safety Study in Healthy Participants
Scientific title
A Phase 1 Study in Healthy Participants to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single-Ascending and Multiple-Ascending Doses of the Influenza A Virus Replication Inhibitor CC-42344
Secondary ID [1] 0 0
CC-42344-P1-001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Influenza A 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - CC-42344
Treatment: Drugs - Placebo

Experimental: SAD cohort 1A - first dose level with 6 active and 2 placebo healthy participants

Experimental: SAD cohort 1B - second dose level with 6 active and 2 placebo healthy participants

Experimental: SAD cohort 1C - third dose level with 12 active and 2 placebo healthy participants; food-effect cohort

Experimental: SAD cohort 1D - fourth dose level with 6 active and 2 placebo healthy participants

Experimental: MAD cohort 2A - first dose level with 6 active and 2 placebo healthy participants dose x 14 days

Experimental: MAD cohort 2B - second dose level with 6 active and 2 placebo healthy participants dose x 14 days

Experimental: MAD cohort 2C - third dose level with 6 active and 2 placebo healthy participants dose x 14 days

Experimental: MAD cohort 2D - forth dose level with 6 active and 2 placebo healthy participants dose x 5 days

Experimental: MAD cohort 2E - forth dose level with 6 active and 2 placebo healthy participants dose x 5 days


Treatment: Drugs: CC-42344
CC-42344 capsules

Treatment: Drugs: Placebo
Placebo capsules
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
treatment emergent adverse events
Timepoint [1] 0 0
Day 1 to 7 days after last dose
Primary outcome [2] 0 0
laboratory abnormalities
Timepoint [2] 0 0
Day 1 to 7 days after last dose
Primary outcome [3] 0 0
vital signs
Timepoint [3] 0 0
Day 1 to 7 days after last dose
Primary outcome [4] 0 0
ECG
Timepoint [4] 0 0
Day 1 to 7 days after last dose
Secondary outcome [1] 0 0
maximum plasma concentration
Timepoint [1] 0 0
Day 1 to 7 days after last dose
Secondary outcome [2] 0 0
time of maximum plasma concentration
Timepoint [2] 0 0
Day 1 to 7 days after last dose
Secondary outcome [3] 0 0
area under the plasma concentration-time curve
Timepoint [3] 0 0
Day 1 to 7 days after last dose
Secondary outcome [4] 0 0
elimination rate constant
Timepoint [4] 0 0
Day 1 to 7 days after last dose
Secondary outcome [5] 0 0
terminal elimination half-life
Timepoint [5] 0 0
Day 1 to 7 days after last dose

Eligibility
Key inclusion criteria
Inclusion Criteria (main):

* Healthy males or healthy, non-pregnant, non-lactating females
* Body weight of at least 50 kg
* Body mass index between =18.0 and =32.0 kg/m2
* Good state of health (mentally and physically)
* Negative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test, if required and per site policy
Minimum age
18 Years
Maximum age
55 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
Exclusion Criteria (main):

* Have received any investigational drug in a clinical research study within the previous 30 days before screening
* Have received any vaccine within 7 days prior to randomization
* History of any drug or alcohol abuse in the past 2 years
* Females of childbearing potential who are pregnant or lactating or planning to become pregnant during the study
* Clinically significant abnormal biochemistry, hematology, coagulation, or urinalysis as judged by the investigator

Study design
Purpose of the study
Other
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Other
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
11/02/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
29/03/2023
Sample size
Target
Accrual to date
Final
80
Recruitment in Australia
Recruitment state(s)
WA
Recruitment hospital [1] 0 0
Linear Clinical Research - Nedlands
Recruitment postcode(s) [1] 0 0
6009 - Nedlands

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Cocrystal Pharma, Inc.
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
Cocrystal Pharma Australia Pty Ltd.
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Commercial sector/industry
Name [2] 0 0
Linear Clinical Research
Address [2] 0 0
Country [2] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
CC-42344 Phase 1 study with single-ascending dose (SAD) and multiple-ascending dose (MAD) parts.
Trial website
https://clinicaltrials.gov/study/NCT05202379
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Sam Salman, MD
Address 0 0
Linear Clinical Research
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05202379